[1] Zeijlemaker W, Gratama JW, Schuurhuis GJ.Tumor hete-rogeneity makes AML a "moving target" for detection of residual disease[J]. Cytometry B Clin Cytom,2014,86(1):3-14.
[2] Paietta E.Should minimal residual disease guide therapy in AML?[J]. Best Pract Res Clin Haematol,2015,28(2-3):98-105.
[3] Wood BL.Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry[J]. Cytometry B Clin Cytom,2016,90(1):47-53.
[4] Spinelli O, Tosi M, Peruta B, et al.Prognostic significance and treatment implications of minimal residual di-sease studies in Philadelphia-negative adult acute lymphoblastic leukemia[J]. Mediterr J Hematol Infect Dis,2014,6(1):e2014062.
[5] Béné MC, Grimwade D, Haferlach C, et al.Leukemia diagnosis: today and tomorrow[J]. Eur J Haematol,2015,95(4):365-373.
[6] Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, et al.Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia[J]. Leukemia,2016,30(3):708-715.
[7] Yu C, Kong QL, Zhang YX, et al.Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia[J]. J Hematol Oncol,2015,8:48.
[8] Chatterjee T, Mallhi RS, Venkatesan S.Minimal residual disease detection using flow cytometry: Applications in acute leukemia[J]. Med J Armed Forces India,2016,72(2):152-156.
[9] 王璐璐, 王建中, 屈晨雪, 等. 八色流式细胞术检测急性B淋巴细胞白血病微小残留病方法的建立[J]. 中华检验医学杂志,2012,35(5):423-430.
